Dr. Roberti Gloria
Linea di ricerca:
Medical activity: Works at IRCCS G.B. Bietti in the offices Via Livenza, 3 and Via di santo Stefano Rotondo 6, at Presidio Ospedaliero Britannico, Rome.
Scientific publication : PubMed
linkedin: Gloria Roberti
2001: High-school graduation at Liceo Ginnasio Statale Giulio Cesare, Rome
2007: Degree in Medicine at University of Rome Tor Vergata, Rome (110/110 e Lode)
2012: Ophthalmology residency at University of Rome Tor Vergata, Rome (50/50 e Lode)
2011-2012: Glaucoma Research fellowship at Moorfields Eye Hospital, London, UK.
2011-2012: Part time glaucoma clinical fellow at Moorfields Eye Hospital, London, UK
2015: Second level Master Open angle glaucoma: epidemiology, diagnosis and therapy, Centro Unimol
Management. University of Molise Campobasso.
2016: High level course Planning and analysis of clinical trials. University of Rome La Sapienza, Rome.
2017: PhD Medical Surgery at University of Rome Tor Vergata, Roma.
2012-2013: Reasercher for Glaucoma Unit, IRCCS- Fondazione G.B. Bietti
2013-today Research and clinical assistance for Glaucoma Unit, IRCCS- Fondazione G.B. Bietti
Member of Italian Society for the study of Glaucoma
Member of Italian Society of Ophthalmology
• Clinical performance of COMPASS in the diagnosis of glaucoma: comparison with HFA.
• To evaluate the efficacy, safety and tolerability of Bimatoprost 0.01% (BIMMD) and Tafluprost single-dose 15 micrograms / Ml (TUDPF) (SAFLUTAN) in patients with glaucoma or ocular hypertension suitable for prostaglandin therapy: European multicenter randomized cross-over, single-blind study, with a masked detective lasting six months. (SPORT II)
• Multicenter, double-blind, randomized, 2-year parallel group study on the safety of LUMIGAN® 0.1 mg / mL versus LUMIGAN® 0.3 mg / mL in patients with glaucoma or ocular hypertension.
• Multicenter prospective randomized double-blind study with control group lasting 6 months to evaluate the safety and efficacy of PG324 compared to Ganfort in patients with increased intraocular pressure.
• Preservative-free fixed combination of tafluprost 0.0015% / timolol 0.5% in patients with open angle glaucoma or ocular hypertension: clinical efficacy, tolerability and safety in clinical practice.
• Safety and efficacy of brinzolamide 1% / brimonidine 0.2% (simbrinza) twice daily as adjuvant therapy to travoprost 0.004% / timolol 0.5% (duotrav)
• Evaluation of the efficacy and safety of T4030 compared to Ganfort UD in patients suffering from ocular hypertension or glaucoma.
• Evaluation of spatial summation in the central 10 degrees of the visual field: development of a neural model for structure-function analysis.
• Evaluation of the concentration of β-amyloid and of intracellular proteolytic pathways on tissues and ocular fluids of patients undergoing glaucoma surgery combined or not with cataract surgery.
• Evaluation of the efficacy of the PreserFlo device in combination or not with cataract surgery in glaucoma patients: multicentre retrospective “before-after” study.
• Assessment of the agreement between different perimeter grids in identifying the central functional defect in glaucoma patients with reduction in the thickness of ganglion cells measured with spectral-domain optical coherence tomography.
• XEN GLAUCOMA TREATMENT REGISTER (XEN-GTR): Italian multicentre prospective observational study
